178 results
S-8
LSTA
Lisata Therapeutics Inc
17 Oct 22
Registration of securities for employees
4:02pm
attorneys’ fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation to the fullest extent permitted under … or investigation, provided that such person provides an undertaking required by the DGCL, to repay such advances if it is ultimately determined that such person
8-K/A
EX-99.1
LSTA
Lisata Therapeutics Inc
4 Oct 22
Other Events
4:42pm
, for failure to comply with the IRB's requirements, or may impose other conditions.
Companies generally divide the clinical investigation of a drug … of the change, it may require prior FDA approval before Cend can implement it. FDA regulations also require investigation and correction of any deviations
8-K
EX-10.2
hy2qorgr7kdb4h77eip
15 Sep 22
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
9:16am
425
lqgdh4sr65dspjr
15 Aug 22
Business combination disclosure
6:46am
424B3
6gy98kee7 amw
29 Jul 22
Prospectus supplement
4:06pm
8-K
EX-2.2
0aabri ljtai6
27 Apr 22
Caladrius Biosciences and Cend Therapeutics Announce
7:05am
8-K
EX-10.2
mr39ce7
27 Apr 22
Caladrius Biosciences and Cend Therapeutics Announce
7:05am
8-K
EX-2.1
v64 48hani0aseo9ez
27 Apr 22
Caladrius Biosciences and Cend Therapeutics Announce
7:05am
8-K
EX-2.3
ejxs61vv8kzxabe1
27 Apr 22
Caladrius Biosciences and Cend Therapeutics Announce
7:05am
8-K
EX-10.1
qp1wqcs3
4 Jun 21
Entry into a Material Definitive Agreement
4:44pm
8-K
EX-10.1
si4o 897nx3bwg
25 Jan 21
Caladrius Biosciences Announces $25.0 Million Private Placement
4:01pm
8-K
EX-10.2
wfdw751pg4 3afaasf
25 Jan 21
Caladrius Biosciences Announces $25.0 Million Private Placement
4:01pm
424B3
r1tg9meyz hlxy
2 Sep 20
Prospectus supplement
4:03pm